Halozyme Therapeutics, Inc.
HALO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $1 | $0 |
| % Growth | 22.4% | 25.6% | 48.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $1 | $1 | $0 |
| % Margin | 84.3% | 76.8% | 78.9% | 81.6% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $1 | $0 | $0 | $0 |
| % Margin | 54.3% | 40.7% | 40.5% | 62.2% |
| Other Income/Exp. Net | $0 | $0 | -$0 | -$0 |
| Pre-Tax Income | $1 | $0 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 43.7% | 34% | 30.6% | 90.8% |
| EPS | 3.5 | 2.13 | 1.48 | 2.86 |
| % Growth | 64.3% | 43.9% | -48.3% | – |
| EPS Diluted | 3.43 | 2.1 | 1.44 | 2.74 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $1 | $0 | $0 | $0 |
| % Margin | 64.7% | 54.5% | 47.8% | 58.4% |